Bruce A. Feinberg, DO

Articles

The Impact of Evolving Treatment Options in Multiple Myeloma, Part 5

November 15, 2021

Joseph Mikhael, MD, reviews the phase 2 GRIFFIN trial evaluating the use of quadruplet therapy, daratumumab plus VRd, in patients with multiple myeloma, and the panel comments on the use of quadruplet therapy.

The Impact of Evolving Treatment Options in Multiple Myeloma, Part 2

November 01, 2021

Ryan Haumschild, PharmD, MS, MBA, comments on the use of triplet regimens as the standard of care treatment for patients with multiple myeloma, and Thomas Ollis, MS, RPh, shares a community practice perspective.